Descrizione

Summary of the evidence supporting Saccharomyces boulardii CNCM I-745 as a unique yeast probiotic with distinct advantages over bacterial probiotics in specific clinical scenarios. Intrinsic antibiotic resistance allows concurrent use with antimicrobial therapy.

Figure 6

Diagram

Source Paper

Unique Properties of Yeast Probiotic Saccharomyces boulardii CNCM I-745: A Narrative Review.

Cureus (2023)

PMID: 37927652

DOI: 10.7759/cureus.46314

Cite This Figure

![Figure 6: Summary of the evidence supporting Saccharomyces boulardii CNCM I-745 as a unique yeast probiotic with distinct advantages over bacterial probiotics in specific clinical scenarios. Intrinsic antibiotic resistance allows concurrent use with antimicrobial therapy.]()

> Source: Sarath Gopalan et al. "Unique Properties of Yeast Probiotic Saccharomyces boulardii CNCM I-745: A Narra." *Cureus*, 2023. PMID: [37927652](https://pubmed.ncbi.nlm.nih.gov/37927652/)

<figure>
  <img src="" alt="Summary of the evidence supporting Saccharomyces boulardii CNCM I-745 as a unique yeast probiotic with distinct advantages over bacterial probiotics in specific clinical scenarios. Intrinsic antibiotic resistance allows concurrent use with antimicrobial therapy." />
  <figcaption>Figure 6. Summary of the evidence supporting Saccharomyces boulardii CNCM I-745 as a unique yeast probiotic with distinct advantages over bacterial probiotics in specific clinical scenarios. Intrinsic antibiotic resistance allows concurrent use with antimicrobial therapy.<br>  Source: Sarath Gopalan et al. "Unique Properties of Yeast Probiotic Saccharomyces boulardii CNCM I-745: A Narra." <em>Cureus</em>, 2023. PMID: <a href="https://pubmed.ncbi.nlm.nih.gov/37927652/">37927652</a></figcaption>
</figure>

Evidenze correlate

Saccharomyces boulardii per Antibiotic-Associated Diarrhea (AAD)

Grado A · 25 studi

Lactobacillus rhamnosus GG per Antibiotic-Associated Diarrhea (AAD)

Grado A · 20 studi

Saccharomyces boulardii per Traveler's Diarrhea

Grado B · 4 studi